Skip to main content
Xbrane Biopharma logo

Xbrane Biopharma — Investor Relations & Filings

Ticker · XBRANE ISIN · SE0007789409 LEI · 5493008DKD05APTKQO39 ST Manufacturing
Open in API
Filings indexed 359 across all filing types
Latest filing 2024-02-27 Share Issue/Capital Cha…
Country SE Sweden
Listing ST XBRANE

About Xbrane Biopharma

https://xbrane.com/en/

Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.

Recent filings

Filing Released Lang Actions
Xbrane publishes prospectus in connection with the company’s partially guaranteed rights issue of approximately SEK 343 million
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated February 27, 2024, announcing that Xbrane Biopharma AB has published a prospectus in connection with a rights issue (a capital raising activity). The text explicitly mentions the approval and registration of the prospectus by the Swedish Financial Supervisory Authority (SFSA) and provides a detailed timetable for the rights issue, including subscription periods and expected outcome announcements. This content strongly relates to financing activities and the formal documentation required for such an event. While it announces a prospectus (which might suggest RPA or LTR if it were just an announcement), the core subject matter is the capital raising/financing event itself, detailed through the rights issue structure. The most fitting category among the provided options for a document detailing a rights issue and associated financing structure is 'Capital/Financing Update' (CAP). It is not a full 10-K, an ER, or a standard IR, but a specific announcement about a capital event.
2024-02-27 English
Xbrane publicerar prospekt i samband med bolagets partiellt garanterade företrädesemission om cirka 343 MSEK
Capital/Financing Update Classification · 98% confidence The document is a press release from Xbrane Biopharma AB dated February 27, 2024, announcing the publication of a prospectus related to a rights issue (företrädesemission) of approximately 343 MSEK. The text explicitly mentions the approval and registration of the prospectus by the Swedish Financial Supervisory Authority (Finansinspektionen) and provides a detailed timeline for the capital raising activities (subscription period, trading of rights, etc.). This content directly relates to fundraising, capital structure changes, and the issuance of securities, which aligns perfectly with the 'Capital/Financing Update' definition. Although a prospectus is mentioned, the document itself is the announcement of that event, but the core subject matter is the financing activity itself, making 'CAP' a stronger fit than 'RPA' (which is usually just announcing the *release* of a report, not the details of a major financing event). Since the document details the financing structure, guarantees, and timeline, it is classified as a Capital/Financing Update.
2024-02-27 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-end report) for the period January–December 2023, published by Xbrane Biopharma. It contains comprehensive financial statements, management commentary (VD-ord), and operational updates for the full fiscal year and the fourth quarter. As it provides substantive financial data and analysis for a period shorter than a full annual report (or as a year-end interim report), it is classified as an Interim/Quarterly Report. FY 2023
2024-02-26 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Year-end report January – December 2023' and contains comprehensive financial statements, including revenue, EBITDA, R&D costs, and earnings per share for both the fourth quarter and the full year. It also includes a CEO's letter, business updates, and a detailed financial summary table. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year (in this case, the year-end report covering the final quarter and the full year). Q4 2023
2024-02-26 English
Rättelse: Kommuniké från extra bolagsstämma i Xbrane Biopharma AB
AGM Information Classification · 98% confidence The document is titled "Rättelse: Kommuniké från extra bolagsstämma i Xbrane Biopharma AB" (Correction: Communication from the Extraordinary General Meeting in Xbrane Biopharma AB). It details decisions made at an Extraordinary General Meeting (EGM), specifically concerning amendments to the articles of association and the approval of a rights issue of units. Since the document reports the decisions and outcomes of a shareholder meeting, it directly relates to AGM/EGM proceedings. Although it is a 'Correction' (Rättelse), the core content is the outcome of the meeting. This aligns best with the 'AGM Information' category (AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM), and by extension, EGMs.
2024-02-22 Swedish
Kommuniké från extra bolagsstämma i Xbrane Biopharma AB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a 'Kommuniké från extra bolagsstämma' (Communiqué from an Extraordinary General Meeting) for Xbrane Biopharma AB. It details the specific decisions made by shareholders during the meeting, including amendments to the articles of association and approval of a rights issue. While it mentions that the full proposals are available on the website, the document itself provides the official results and resolutions of the meeting, which classifies it as a Declaration of Voting Results (DVA).
2024-02-22 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.